A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled in 4 indication-specific expansion cohorts to determine the efficacy, short- and long-term safety, and tolerability of revumenib.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza aktywnej ostrej białaczki (limfoblastycznej lub mieloblastycznej) potwierdzna badaniami szpiku kostnego
- •Białaczka z określonymi zmianami genetycznymi (KMT2A, NUP98 lub NPM1) vidoczna w szpiku kostnym
- •Liczba białych krwinek poniżej 25 000/mikolitr w momencie włączenia do badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 30 Days
- Last updated (source)
- October 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (57)
City of Hope Comprehensive Cancer Center
Duarte, United States
University Of California Care Medical Group - Norris Comprehensive Cancer Center And Hospital
Los Angeles, United States
Stanford Cancer Institute
Palo Alto, United States
University of Colorado
Aurora, United States
Florida Cancer Specialists and Research Institute
Sarasota, United States
Moffitt Cancer Center
Tampa, United States
Emory Winship Cancer Institute
Atlanta, United States
Children's Healthcare of Atlanta
Atlanta, United States
The University of Chicago Medical Center
Chicago, United States
University of Iowa Hospital
Iowa City, United States
Dana Farber Cancer Institute
Boston, United States
Washington University in St. Louis School of Medicine
St Louis, United States
Hackensack University Medical Center
Hackensack, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Montefiore Medical Center
New York, United States
Duke University Medical Center
Durham, United States
University of Cincinnati
Cincinnati, United States
Ohio State University
Columbus, United States
Oregon Health & Science University
Portland, United States
University of Pennsylvania
Philadelphia, United States
The University of Texas MD Anderson Cancer Center
Houston, United States
Huntsman Cancer Institute at the University of Utah
Salt Lake City, United States
Peter MacCallum Cancer Centre (PMCC)
Melbourne, Australia
Royal Melbourne Hospital (RMH)
Parkville, Australia
Alfred Hospital
Melbourne, Australia
Sir Charles Gairdner Hospital
Nedlands, Australia
Royal North Shore Hospital
Saint Leonards, Australia
University Health Network
Toronto, Canada
The Hospital for Sick Children
Toronto, Canada
Hospital Saint-Louis - APHP
Paris, France
Centre Hospitalier Universitaire (CHU) de Bordeaux
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Institut Gustave Roussy-Gustave Roussy Cancer Center -DITEP
Villejuif, France
University Hospital Of Ulm, Universitatsklinikum Ulm
Ulm, Germany
Universitaetsklinikum Essen (AoR)
Essen, Germany
Universitaetsmedizin Greifswald
Greifswald, Germany
Universitaetsmedizin Der Johannes
Gutenberg, Germany
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
University of Leipzig
Leipzig, Germany
Klinikum Nuernberg Nord
Nuremberg, Germany
Rambam Health Care Campus (RHCC)
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Hadassah Medical Center- Ein Kerem
Jerusalem, Israel
Galilee Medical Center
Nahariya, Israel
Rabin Medical Center
Petah Tikva, Israel
Sheba Medical Center
Ramat Gan, Israel
IRCCS Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy
Istituto Romagnolo Per Lo Studio dei tumori Dino Amadori
Meldola, Italy
IRCCS-Istituto Europeo di Oncologia
Milan, Italy
Universita Cattolica Fondazione Policlinico Agostino Gemelli
Roma, Italy
S Bortolo Hospital AULSS 8 Berica
Vicenza, Italy
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania
Princess Maxima Center for Pediatric Oncology
Utrecht, Netherlands
Hospital Centro Comprensivo de Cancer UPR
San Juan, Puerto Rico
Institut Catala d'Oncologia (ICO) - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Trial contact
Syndax Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.